Clinical trials
Immunity clinical trials
Below are recruiting immunity clinical trials, each written for real people, not researchers. We’re tracking 1,064 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07125079Recruiting
Studying immune cells and a new treatment for ARDS
This study looks at how the immune system responds in people with ARDS (a severe lung injury) and tests a new treatment called PIP-2 in the lab to see if it might help. It aims to better understand lung injury and find new ways to treat it.
Philadelphia, PennsylvaniaAges 21–90 - NCT07128095Recruiting
Wellness and nutrition check during COVID-19
This study looks at how exercise, nutrition, and overall wellness have been affected during the COVID-19 pandemic. It may help you understand how to improve your health habits.
Bloomington, IndianaAges 18–75 - NCT07130032RecruitingPhase 2
Immunotherapy combo for advanced lung cancer or melanoma
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT07131020Recruiting
Moxibustion for immune function in stable COPD
This study tests whether a type of moxibustion (a traditional Chinese heat therapy) called Yifei Moxibustion can help improve immune function in people with stable COPD. Researchers will look at tiny particles in your blood called exosomes to understand how the treatment works.
Zhengzhou, HenanAges 18–80 - NCT07131566Recruiting
Immune response in neck lymph nodes in head and neck cancer
This study looks at how the immune system in the lymph nodes of the neck responds to head and neck cancer. It will help researchers understand how the body fights these cancers, which could lead to better treatments.
Stockholm, Stockholm CountyAges 18 years+ - NCT07131956Recruiting
Immune biomarkers in prostate cancer brachytherapy
This study looks at immune system markers in men getting brachytherapy (internal radiation) for prostate cancer. It may help us understand how the body responds to this treatment.
Augsburg, BavariaAges 18 years+ - NCT07137247Recruiting
How the immune system changes over time in chronic hepatitis B
This study tracks how the immune system works in people with chronic hepatitis B who haven't taken antiviral medication in the last 6 months. It aims to understand the natural history of the infection without treatment.
Guangzhou, GuangdongAges 1–80 - NCT07138222Recruiting
Immune therapy and fertility in women and men with melanoma
This study looks at how immune checkpoint inhibitors (a type of immunotherapy) affect fertility and hormone health in premenopausal women and men with melanoma. It aims to understand and manage these side effects while you receive treatment.
Sydney, New South WalesAges 18–60 - NCT07141056Recruiting
Emotional stress and immunotherapy for liver cancer
This study looks at how emotional stress affects how well immunotherapy works for liver cancer. It is for people with liver cancer who are about to start immunotherapy, either before or after surgery, or as first treatment for advanced cancer.
Zhanjiang, GuangdongAges 18 years+ - NCT07148245Recruiting
Study of immunotherapy side effects in melanoma
This study looks at how people with advanced melanoma (a serious skin cancer) feel during treatment with immunotherapy. It aims to better understand the symptoms they experience, so doctors can help manage them.
San Francisco, CaliforniaAges 18 years+ - NCT07154615Recruiting
Immune system study in sepsis patients
This study looks at how the immune system changes in people with sepsis (a severe response to infection that can cause organ failure). It aims to understand immune dysfunction to help improve treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT07161310Recruiting
Urolithin A with immunotherapy for newly diagnosed solid tumors
This trial tests adding a natural supplement called urolithin A to standard first-line immunotherapy for people with newly diagnosed solid tumors who have not yet had any cancer treatment. The goal is to see if it makes the immunotherapy work better.
FrankfurtAges 18 years+ - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07175493RecruitingPhase 1/Phase 2
CM336 for relapsed or refractory autoimmune cytopenia
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
Zhengzhou, HenanAges 18 years+ - NCT07177417RecruitingPhase 4
How the immune system responds to FluMist in the airways
This study tests how the immune system in your nose and airways responds to the FluMist nasal spray flu vaccine. It may help doctors understand why some people get better protection from the flu.
St Louis, MissouriAges 18–40 - NCT07177729Recruiting
Tick Bite Study – Understanding Immune Reactions
This study looks at how the body reacts to tick bites, specifically to understand alpha-gal syndrome—a condition that can cause allergic reactions to red meat. If you had a recent tick bite and can provide the tick, you may be able to help researchers learn more.
LuxembourgAges 18 years+ - NCT07180927RecruitingPhase 1/Phase 2
DLL3 car-t therapy for recurrent brain tumors
This trial tests a new immune therapy called DLL3 CAR-T cells for people with brain tumors that have come back or not responded to treatment. It aims to see if these specially designed cells can attack the tumor safely.
Shenzhen, GuangdongAges 2–70 - NCT07186621RecruitingPhase 3
Testing immunotherapy or chemoembolization after liver cancer surgery
This trial compares two treatments after liver cancer surgery to see which better prevents the cancer from coming back. You may be eligible if your surgery had a narrow margin and you have certain risk factors, like a tumor over 5 cm or high AFP levels.
BeijingAges 18–80 - NCT07187713RecruitingPhase 4
Study of ACE Reno, Pico Cell Matrix for kidney health
This trial tests a new treatment called ACE Reno, Pico Cell Matrix to see if it can improve kidney function in people with chronic kidney disease (CKD) at various stages. It may be an option if you have early to moderate kidney issues (including after a transplant) and are already on standard therapies.
Giza, GZAges 18–80 - NCT07189117Recruiting
Study of cell metabolism in blood cancers
This study looks at how blood cancer cells use energy (metabolism) and how that affects the immune system. Researchers hope to find new ways to treat these cancers by understanding cell metabolism better.
BaselAges 18 years+ - NCT07189936RecruitingPhase 2
Testing 2-HOBA for Immune Issues in Long COVID with POTS
This trial tests if a medication called 2-HOBA can help with ongoing immune system issues in people with Long COVID who also have POTS. It aims to reduce fatigue and other symptoms by calming overactive immune responses.
Nashville, TennesseeAges 18 years+ - NCT07191171Recruiting
Gut bacteria drugs and immunotherapy in lung cancer
This study looks at whether certain drugs (like antibiotics or other gut-bacteria-affecting medications) influence how well immunotherapy works for advanced non-small cell lung cancer. It may help find ways to improve treatment outcomes.
StrasbourgAges 18 years+ - NCT07192458RecruitingPhase 2
High vs. Standard Dose Flu Vaccine in Lung Transplant
This study compares a high-dose flu vaccine to the standard dose in lung transplant recipients. It aims to see if a higher dose gives better protection against the flu.
Nashville, TennesseeAges 18 years+ - NCT07193966RecruitingPhase 1/Phase 2
CAR-T cell therapy for advanced melanoma using NG2 and DLL3 targets
This trial tests a new treatment using your own immune cells (CAR-T cells) that are modified to find and attack melanoma cells with specific markers called NG2 and DLL3. It is for people whose melanoma has spread or come back after standard treatments.
Shenzhen, GuangdongAges 18–75
Hear when a new Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunity?
- Yes. Clin2 currently lists 1,064 recruiting immunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.